These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 24780456)

  • 21. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
    Banerjee D; Winocour P; Chowdhury TA; De P; Wahba M; Montero R; Fogarty D; Frankel AH; Karalliedde J; Mark PB; Patel DC; Pokrajac A; Sharif A; Zac-Varghese S; Bain S; Dasgupta I;
    BMC Nephrol; 2022 Jan; 23(1):9. PubMed ID: 34979961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating hypertension in the patient with overt diabetic nephropathy.
    Lewis EJ
    Semin Nephrol; 2007 Mar; 27(2):182-94. PubMed ID: 17418687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertensive nephropathy: prevention and treatment recommendations.
    Hart PD; Bakris GL
    Expert Opin Pharmacother; 2010 Nov; 11(16):2675-86. PubMed ID: 20718588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 28. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC; Navis G; Laverman GD
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
    Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
    J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current state of RAAS blockade in the treatment of hypertension and proteinuria.
    Kalaitzidis RG; Bakris GL
    Curr Cardiol Rep; 2009 Nov; 11(6):436-42. PubMed ID: 19863868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
    Majewski C; Bakris GL
    Curr Diab Rep; 2016 Apr; 16(4):24. PubMed ID: 26879307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
    Basi S; Lewis JB
    Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should albuminuria be a therapeutic target in patients with hypertension and diabetes?
    de Zeeuw D
    Am J Hypertens; 2004 Nov; 17(11 Pt 2):11S-15S; quiz A2-4. PubMed ID: 15539105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
    Turgut F; Balogun RA; Abdel-Rahman EM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.